MagPortal.com   Clustify - document clustering
 Home  |  Newsletter  |  My Articles  |  My Account  |  Help 
Similar Articles
The Motley Fool
December 13, 2007
Brian Lawler
Biogen Can't Find a Buyer After formally putting itself up for sale two months ago, Biogen Idec announces that it can't find any takers. mark for My Articles similar articles
The Motley Fool
October 16, 2007
Brian Lawler
Questions Surround a Biogen Deal Rumors swirl around Biogen after it publicly announces that it's for sale. Investors, take note. mark for My Articles similar articles
The Motley Fool
November 6, 2007
Brian Lawler
It's All About VELCADE at Millennium Millennium Pharmaceuticals announces a strong quarter of financial results. mark for My Articles similar articles
The Motley Fool
August 5, 2008
Brian Lawler
An ImClone Deal Will Get Done Despite his tough talk, Icahn will likely complete a buyout of ImClone. mark for My Articles similar articles
The Motley Fool
May 2, 2007
Brian Lawler
Biogen's Measured Growth The biopharmaceutical reports first-quarter financial results. Investors, take note. mark for My Articles similar articles
The Motley Fool
February 7, 2008
Brian Lawler
Biogen Rests Rumors The pharmaceutical announces its year-end financial results, and squashes rumors that it is considering a major acquisition. mark for My Articles similar articles
The Motley Fool
July 26, 2006
Brian Lawler
Biogen Slows Down Several potential growth drivers should help the biopharma. Ever since the merger with Idec, the company has been fairly well run (absent the Tysabri delays). Investors, take note. mark for My Articles similar articles
The Motley Fool
December 4, 2007
Brian Lawler
Another Drug Deal Goes Down Canadian specialty pharma Axcan Pharma became the latest drugmaker to be acquired by a private equity group -- for $1.3 billion in cash. mark for My Articles similar articles
The Motley Fool
July 23, 2008
Brian Lawler
No Picking at Biogen At a time in which all of its top drugs experienced at least double-digit percentage sales growth, there aren't many issues to poke at with Biogen Idec's just-released second-quarter financial results. mark for My Articles similar articles
The Motley Fool
March 8, 2005
Charly Travers
After the Crash, Is Biogen IDEC a Buy? Biogen stock plunge may be an overreaction to pulling multiple sclerosis drug Tysabri off the market. mark for My Articles similar articles
The Motley Fool
August 29, 2008
Brian Lawler
Will Biopharma Acquisitions Never Cease? In both the size and quantity of proposed deals, the past 24 months have been busier than ever for biopharma dealmakers. What's behind all this activity? mark for My Articles similar articles
The Motley Fool
June 11, 2008
Brian Lawler
He Said, Biogen Said Pharmaceutical Biogen Idec's battle with Carl Icahn is coming to a head. mark for My Articles similar articles
The Motley Fool
January 29, 2008
Brian Lawler
Icahn Tries to Board USS Biogen Carl Icahn and the funds that he runs announce that they will try to get elected to three seats on the board of directors at Biogen Idec. mark for My Articles similar articles
The Motley Fool
February 6, 2009
Brian Orelli
Icahn vs. Biogen: Round 2 On the heels of an announcement that he'll try to get seats on Amylin Pharmaceuticals' board, Icahn is also angling for seats on Biogen Idec's board. mark for My Articles similar articles
The Motley Fool
May 29, 2008
Brian Lawler
Icahn Girds for Biogen Battle The activist investor officially launches his bid to usurp Biogen's board of directors. mark for My Articles similar articles
The Motley Fool
April 25, 2008
Brian Lawler
Biogen's Big Step Forward Pharmaceutical company Biogen IDEC boasts better results and a rosier outlook. mark for My Articles similar articles
The Motley Fool
December 4, 2009
Brian Orelli
Our Final Offer (Maybe)! That's a FACT! Biogen ups its bid for Facet. mark for My Articles similar articles
The Motley Fool
October 15, 2007
Brian Lawler
PDL BioPharma's Best Hope The data on daclizumab for multiple sclerosis is encouraging. Investors, take note. mark for My Articles similar articles
The Motley Fool
July 24, 2007
Brian Lawler
Biogen's Steady Growth Biogen reports another good quarter of growth, both top- and bottom-line. mark for My Articles similar articles
The Motley Fool
February 8, 2005
Charly Travers
Good Prognosis for Biogen IDEC Blockbuster products help the biotech firm continue its stellar performance. mark for My Articles similar articles
The Motley Fool
January 9, 2008
Brian Lawler
Checking In on Biogen Biogen Idec presents at the JPMorgan Healthcare Conference, reiterating its long-term guidance of 15% compound annual sales growth and 20% average non-GAAP earnings-per-share growth from 2007 through 2010. mark for My Articles similar articles
The Motley Fool
July 21, 2010
Brian Orelli
Biogen Looks Good Now, but What About Tomorrow? Biogen Idec saw revenue increase 11% and adjusted earnings per share jump almost 75%, which is all well and good, but the longer-term prospects for the company aren't nearly as impressive. mark for My Articles similar articles
The Motley Fool
August 1, 2008
Brian Lawler
Elan Becomes a Bad News Buy Shares of Elan are now undervalued, thanks to a big price drop following bad new about their multiple sclerosis drug. mark for My Articles similar articles
The Motley Fool
May 13, 2009
Brian Orelli
Icahn's an Energizer Pit Bull He keeps going and doesn't let go. mark for My Articles similar articles
Chemistry World
February 8, 2013
Andrew Turley
Biogen buys Tysabri from Elan for $3.25bn US biotech Biogen Idec is to pay $3.25 billion to Irish drugmaker Elan for full rights to Tysabri (natalizumab) injections for the treatment of multiple sclerosis. mark for My Articles similar articles
The Motley Fool
September 11, 2008
Brian Lawler
ImClone and Bristol-Myers' Unfinished Business ImClone rejects Bristol's offer, but likely isn't done dealing with it yet. mark for My Articles similar articles
The Motley Fool
May 5, 2006
Stephen D. Simpson
Biogen Idec Needs a Booster Tysabri had better come back strong, or growth could come up short for this biotech. Investors, take note. mark for My Articles similar articles
The Motley Fool
October 31, 2011
Brian Orelli
When You've Got It, You've Got It Biogen keeps its good-news streak going. mark for My Articles similar articles
The Motley Fool
September 24, 2008
Brian Lawler
Bristol-Myers Puts Icahn and ImClone to the Test Despite trying to project different intentions last week, pharma giant Bristol-Myers Squibb raised its bid for ImClone Systems. mark for My Articles similar articles
The Motley Fool
November 30, 2007
Brian Lawler
MGI's Turn for "Strategic Alternatives" MGI Pharma is the latest in a growing list of drugmakers looking for someone to acquire them. The company may be a relatively more attractive takeover target than other drugmakers, because it's two lead drugs are unpartnered in the U.S. mark for My Articles similar articles
The Motley Fool
June 1, 2009
Brian Orelli
Going Up for All the Wrong Reasons Bristol-Myers has been identified as Elan's mystery bidder. So what? mark for My Articles similar articles
The Motley Fool
September 4, 2009
Brian Orelli
Takeover Likely? Management Says No! A hostile bid that management didn't want. Biogen Idec announced today that it's willing to buy Facet Biotech for $14.50 per share. mark for My Articles similar articles
The Motley Fool
January 29, 2010
Brian Orelli
Icahn Back to Batter Biogen The old guy has tenacity. mark for My Articles similar articles
The Motley Fool
May 31, 2007
Tim Beyers
Biogen's $3 Billion Bet There are times when a buyback is not only appropriate, but also smart. This is one of those times for Biogen Idec. It's a chance for management to deliver huge returns to long-suffering shareholders. mark for My Articles similar articles
The Motley Fool
November 1, 2006
Brian Lawler
Biogen Idec's Booming Results Even with guidance for 2006 non-GAAP earnings per share raised to more than $2.20, Biogen shares are trading at a reasonable 24 times earnings, considering the level of scale and sales growth it has exhibited this year. mark for My Articles similar articles
The Motley Fool
February 10, 2010
Brian Orelli
Icahn's Smiling -- Should We Be? Biogen Idec's fourth quarter results must have made Carl Icahn smile. But the guidance for next year gives pause. mark for My Articles similar articles
The Motley Fool
September 22, 2008
Brian Lawler
Why Bristol-Myers Won't Pull Its ImClone Bid Bristol-Myers might drop its cash bid of $60 per share to acquire longtime partner ImClone Systems. mark for My Articles similar articles
The Motley Fool
January 5, 2010
Brian Orelli
Biogen Idec's CEO Calls It Quits And the market seems to be saying to him don't let the door hit you on the way out. mark for My Articles similar articles
The Motley Fool
June 30, 2010
Ryan McBride
Reports: Biogen Picks Exelixis Chief George Scangos as New CEO George Scangos, a microbiologist by training, has been CEO of the South San Francisco-based cancer drug developer Exelixis since 1996, and takes over at Biogen immediately. mark for My Articles similar articles
The Motley Fool
August 29, 2006
Brian Lawler
More Good News for Rituxan Genentech and Biogen Idec's drug shows positive results against multiple sclerosis. Investors, take note. mark for My Articles similar articles
The Motley Fool
October 7, 2008
Brian Orelli
Eli Lilly's Risky Gamble Eli Lilly is desperate, and the high acquisition price of ImClone shows it. mark for My Articles similar articles
The Motley Fool
November 18, 2008
Brian Orelli
Icahn's Next Biotech Adventure With ImClone done, he's got his eye focused elsewhere. mark for My Articles similar articles
Chemistry World
July 31, 2013
Daniel Johnson
Perrigo bags Elan and its bargain Irish tax rates US drugmaker Perrigo has agreed to buy Irish pharma company Elan in a deal worth $8.6 billion. This hands Perrigo a base in low-tax Ireland and annual savings of up to $150 million in tax and operating costs. mark for My Articles similar articles
The Motley Fool
June 8, 2010
Ryan McBride
Biogen's CEO Retires, COO to Follow A replacement won't be announced for a few weeks. mark for My Articles similar articles
The Motley Fool
December 16, 2009
Brian Orelli
No Holiday Goodwill Twixt Biogen and Facet Biogen and Facet are still at it, as their nasty takeover fight continues. mark for My Articles similar articles
The Motley Fool
March 16, 2007
Brian Lawler
PDL's Friend Comes Through PDL and partner Biogen advance one of their lead drug candidates. Investors, take note. mark for My Articles similar articles
The Motley Fool
August 1, 2008
Brian Lawler
Is $60 a Share Enough for ImClone? Bristol-Myers Squibb announced a $60-per-share offer for ImClone Systems, but are shareholders going to go for the deal? mark for My Articles similar articles
The Motley Fool
July 17, 2009
Brian Orelli
Tysabri Is Back! News about Biogen Idec and Elan's multiple sclerosis drug revenues, as well as those of Pfizer and Teva. mark for My Articles similar articles
The Motley Fool
March 11, 2005
Karl Thiel
Better Times at Biogen IDEC Is now the time to buy this pharmaceutical? mark for My Articles similar articles
The Motley Fool
August 21, 2008
Brian Lawler
PDL BioPharma's Partnership Makes Sense Bristol-Myers assumes some of the risk of developing a drug for bone marrow cancer. mark for My Articles similar articles